Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIO: Rituximab vs Ocrelizumab in Relapsing-remitting Multiple Sclerosis
NCT05758831Phase 3Recruiting
- Sponsor
- CHU Rennes
- Start
- Jun 2023
- Primary completion
- Mar 2030
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab in relapsing-remitting multiple sclerosis (RRMS) (2 arms), sponsored by CHU Rennes. Primary endpoint: Percentage of patients without disease activity at 2 years. Started Jun 2023; status: recruiting.
02
Drugs
rituximab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT05758831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05758831.